Proof 302: A Randomized, Double-Blind, Placebo-Controlled, Phase Iii Trial Of Infigratinib As Adjuvant Therapy In Patients With Invasive Urothelial Carcinoma Harboring Fgfr3 Alterations
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要